Nasdaq:SGMO
SANGAMO THERAPEUTICS, INC
A gene editing biotech firm utilizing CRISPR technology to develop curative therapies for rare genetic disorders.
Key Metrics
Investment Thesis
Bull Case
Sangamo possesses a best-in-class CRISPR platform with potential for breakthrough curative therapies that could generate significant value upon FDA approval. Strategic collaborations provide an immediate pipeline of potential commercial products and mitigate the need for massive upfront commercialization costs. If key clinical trials succeed, the company could transition from a cash-burning R&D phase to a high-margin licensing model similar to successful gene therapy peers.
Bear Case
Revenue has collapsed to $57.8 million in 2024 after peaking at $176.2 million in 2023, raising concerns about the sustainability of current business models and partnership structures. The company holds a substantial retained earnings deficit of -$1.5 billion and carries liabilities exceeding assets, indicating high financial distress risk. With operating expenses reaching $161.8 million against only $57.8 million in revenue, the path to profitability appears distant without new major financing events.
About SANGAMO THERAPEUTICS, INC
Sangamo Therapeutics is a biotechnology company focused on developing gene editing therapies primarily for rare genetic diseases. The company leverages its proprietary CRISPR-Cas9 technology to create precise treatments, with recent revenue activity centered on collaboration agreements and licensing arrangements within the specialized gene therapy market.
Analysis
Management Discussion
The company reported a net loss of $97.9 million in 2024, reflecting the continued heavy investment in research and development despite a sharp decline in revenue from previous years. While cash flow from financing activities provided $28.4 million in capital injections, the operating cash flow remained negative at -$67.1 million due to substantial non-cash adjustments and working capital changes. The gross profit margin structure indicates reliance on upfront licensing payments rather than product sales, resulting in revenue contraction as initial deal structures mature.
Industry Overview
The gene therapy sector is experiencing rapid innovation but faces intense regulatory scrutiny and high development costs before any product can reach the market. Companies in this space often operate as cash-burning entities until their first approved therapy generates sales or licensing fees. Success depends heavily on navigating complex FDA approval processes for novel modalities like CRISPR-based treatments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $111.3M | $176.2M | $57.8M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $111.3M | $176.2M | $57.8M |
| Operating Expenses | $312.6M | $450.2M | $161.8M |
| Operating Income | $-201.3M | $-274.0M | $-104.0M |
| R&D | $249.9M | $234.1M | $111.5M |
| G&A | $62.7M | $61.2M | $44.7M |
| Stock-Based Comp | $31.6M | $27.4M | $12.4M |
| D&A | $12.1M | $15.1M | $5.1M |
| Other OpEx | $0 | $155.0M | $5.5M |
| Non-Operating Income | $9.4M | $11.1M | $5.9M |
| Pre-Tax Income | $-191.8M | $-262.9M | $-98.1M |
| Income Tax | $429.0K | $-5.1M | $-167.0K |
| Continuing Ops | $-192.3M | $-257.8M | $-97.9M |
| Discontinued Ops | $0 | $0 | $0 |
| Net Income | $-192.3M | $-257.8M | $-97.9M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $-192.3M | $-257.8M | $-97.9M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $300.3M | $94.3M | $51.7M |
| Cash & Equivalents | $100.4M | $45.2M | $41.9M |
| Accounts Receivable | $3.7M | $923.0K | $526.0K |
| Prepaid Expenses | $18.2M | $12.0M | $5.2M |
| Other Current Assets | $178.0M | $36.2M | $4.1M |
| Long-Term Assets | $262.2M | $71.0M | $49.9M |
| PP&E (Net) | $63.5M | $26.9M | $17.9M |
| Intangibles | $50.7M | $0 | $0 |
| Goodwill | $37.6M | $0 | $0 |
| Operating Leases | $62.0M | $26.0M | $16.9M |
| Other LT Assets | $48.4M | $18.1M | $15.2M |
| Total Assets | $562.5M | $165.3M | $101.6M |
| Current Liabilities | $111.7M | $47.7M | $45.8M |
| Accounts Payable | $22.4M | $15.3M | $15.5M |
| Current Leases | $4.1M | $4.6M | $4.3M |
| Deferred Revenue | $51.8M | $0 | $7.6M |
| Other Current Liab | $17.4M | $4.3M | $10.3M |
| Long-Term Liabilities | $155.8M | $34.7M | $33.1M |
| LT Operating Leases | $39.0M | $33.5M | $26.3M |
| Other LT Liab | $7.5M | $1.2M | $933.0K |
| Total Liabilities | $267.6M | $82.4M | $78.9M |
| Shareholders' Equity | $295.0M | $82.9M | $22.8M |
| Retained Earnings | $-1.15B | $-1.41B | $-1.50B |
| AOCI | $-8.4M | $-4.6M | $-7.5M |
| Total L&E | $562.5M | $165.3M | $101.6M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $-192.3M | $-257.8M | $-97.9M |
| Non-Cash Adjustments | $42.7M | $215.6M | $37.0M |
| Working Capital Changes | $-74.0M | $-182.6M | $-6.2M |
| Cash from Operations | $-223.6M | $-224.8M | $-67.1M |
| Capital Expenditures | $20.2M | $21.2M | $267.0K |
| Cash from Investing | $59.3M | $153.5M | $37.5M |
| Cash from Financing | $84.7M | $14.6M | $28.4M |
| FX Effect | $1.3M | $1.5M | $-2.0M |
| Net Change in Cash | $-78.4M | $-55.2M | $-3.3M |
| Beginning Cash | $180.4M | $101.9M | $46.7M |
| Ending Cash | $101.9M | $46.7M | $43.4M |
Frequently Asked Questions
How does SANGAMO THERAPEUTICS, INC make money?
Licensing and collaboration revenues from strategic partnerships, including notable deals with major pharmaceutical entities. Research and development expenditures directed toward advancing proprietary gene editing platforms for specific disease indications. Intellectual property monetization through patent licensing and royalty streams derived from external product commercialization.
What are the main risks for SGMO?
Significant ongoing net losses driven by high research and development costs totaling over $111 million in the latest period. Dependence on external collaboration partners for future revenue generation, creating vulnerability to partnership termination or regulatory hurdles. Regulatory approval timelines for gene therapies are lengthy and uncertain, potentially delaying return on investment for years. Limited cash reserves relative to total liabilities pose liquidity challenges if operating burn rates do not decrease.
What is SGMO's competitive advantage?
Proprietary CRISPR-Cas9 platform offering high precision and efficiency in targeting genetic mutations compared to competitors. Strong intellectual property portfolio protecting core gene editing technologies and associated delivery mechanisms. Established strategic partnerships with industry leaders providing access to capital and commercial expertise without requiring full build-out of internal manufacturing.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.